NASDAQ:EXAS Exact Sciences - EXAS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. $71.58 +3.47 (+5.09%) (As of 02/2/2023 11:53 AM ET) Add Compare Share Share Today's Range$69.43▼$71.8750-Day Range$41.19▼$68.9652-Week Range$29.27▼$84.31Volume802,654 shsAverage Volume3.13 million shsMarket Capitalization$12.72 billionP/E RatioN/ADividend YieldN/APrice Target$61.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exact Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.58 Rating ScoreUpside/Downside12.8% Downside$61.57 Price TargetShort InterestBearish7.23% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.60Based on 8 Articles This WeekInsider TradingSelling Shares$60,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.67) to ($2.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 starsMedical Sector884th out of 1,030 stocksMedical Laboratories Industry21st out of 25 stocks 1.3 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 7 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $61.57, Exact Sciences has a forecasted downside of 12.8% from its current price of $70.59.Amount of Analyst CoverageExact Sciences has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.23% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Exact Sciences has recently increased by 11.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private colorectal cancer diagnostics services" product. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.55. Previous Next 3.1 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Exact Sciences this week, compared to 3 articles on an average week.Search Interest32 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows16 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,000.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions90.30% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($3.67) to ($2.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -17.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -17.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exact Sciences (NASDAQ:EXAS) StockEXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.Read More Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Stock News HeadlinesJanuary 10, 2023 | marketbeat.comExact Sciences Corp Stock Price Is Trending Up Here's WhyExact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter.January 10, 2023 | marketbeat.comExact Sciences Corp Stock Price Is Trending Up Here's Why (EXAS)Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter.February 2, 2023 | Investing Trends (Ad)The Biggest "Missing Ingredient" in the $7 Trillion EV MarketChina has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.February 2, 2023 | finance.yahoo.com1 Soaring Growth Stock to Buy and Hold for 10 YearsFebruary 1, 2023 | finance.yahoo.comExact Sciences schedules fourth quarter 2022 earnings callJanuary 30, 2023 | finance.yahoo.comHere's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth TodayJanuary 26, 2023 | finance.yahoo.comCathie Wood: Ark Continues Exact Sciences DumpJanuary 25, 2023 | msn.com'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past MonthFebruary 2, 2023 | PressReach (Ad)Top AI Tech Stock To WatchToday's stock market news features a Robotics stock with blue sky potential.January 25, 2023 | msn.comCathie Wood sells 100K shares of Exact SciencesJanuary 24, 2023 | finance.yahoo.comBetter Long-Term Buy in 2023: Exact Sciences or Veracyte?January 20, 2023 | finance.yahoo.comCathie Wood Is Crushing It This Year Thanks To 9 StocksJanuary 19, 2023 | finance.yahoo.comExact Sciences (EXAS) Stock Moves -0.67%: What You Should KnowJanuary 16, 2023 | finance.yahoo.comIs There An Opportunity With Exact Sciences Corporation's (NASDAQ:EXAS) 50% Undervaluation?January 13, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Jinko Solar, American Airlines and Exact SciencesJanuary 13, 2023 | finance.yahoo.comHere's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade AgoJanuary 12, 2023 | finance.yahoo.com3 Top Stocks Already up More Than 20% In 2023January 12, 2023 | benzinga.comWill Investors Notice Exciting Sign On Exact Sciences's Chart?January 12, 2023 | finance.yahoo.comIs Exact Sciences a Buy?January 12, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Exact Sciences (EXAS)January 11, 2023 | benzinga.comCathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, TeslaJanuary 11, 2023 | finance.yahoo.comCathie Wood Key Fund Sees Exact Sciences Take Top Spot From ZoomJanuary 10, 2023 | finance.yahoo.comIs Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?January 10, 2023 | finance.yahoo.comStrength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?January 10, 2023 | finance.yahoo.comExact Sciences moves up time to profitability to most recent quarterJanuary 10, 2023 | thestreet.comStock To Watch: Exact Sciences Corporation (EXAS) In Perilous ReversalJanuary 9, 2023 | msn.comMidday movers: Lululemon Athletica, CinCor Pharma, Exact Sciences and moreSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Company Calendar Last Earnings11/01/2021Today2/02/2023Next Earnings (Estimated)2/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,500Year Founded1995Price Target and Rating Average Stock Price Forecast$61.57 High Stock Price Forecast$85.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside-14.0%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($4.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-595,630,000.00 Net Margins-35.73% Pretax Margin-36.28% Return on Equity-22.10% Return on Assets-11.06% Debt Debt-to-Equity Ratio0.72 Current Ratio2.47 Quick Ratio2.20 Sales & Book Value Annual Sales$1.77 billion Price / Sales7.20 Cash FlowN/A Price / Cash FlowN/A Book Value$19.66 per share Price / Book3.64Miscellaneous Outstanding Shares177,680,000Free Float175,374,000Market Cap$12.72 billion OptionableOptionable Beta1.42 Social Links Key ExecutivesKevin T. ConroyChairman, President & Chief Executive OfficerJeffrey Thomas ElliottExecutive VP, Chief Operating & Financial OfficerSandra StatzSenior VP-Clinical & Regulatory AffairsGary FringsChief Information OfficerScott C. JohnsonSenior Vice President-Assay Research & DevelopmentKey CompetitorsQuest DiagnosticsNYSE:DGXNateraNASDAQ:NTRAGuardant HealthNASDAQ:GHLaboratory Co. of AmericaNYSE:LHSmith & NephewNYSE:SNNView All CompetitorsInsiders & InstitutionsState of New Jersey Common Pension Fund DBought 2,920 shares on 2/1/2023Ownership: 0.063%DekaBank Deutsche GirozentraleSold 3,909 shares on 2/1/2023Ownership: 0.025%Janney Montgomery Scott LLCBought 2,153 shares on 2/1/2023Ownership: 0.006%Great Valley Advisor Group Inc.Sold 385 shares on 2/1/2023Ownership: 0.004%CWM LLCBought 354 shares on 2/1/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions EXAS Stock - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price forecast for 2023? 12 brokers have issued 12 month price targets for Exact Sciences' stock. Their EXAS share price forecasts range from $35.00 to $85.00. On average, they expect the company's stock price to reach $61.57 in the next year. This suggests that the stock has a possible downside of 9.6%. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2023? Exact Sciences' stock was trading at $49.51 at the beginning of 2023. Since then, EXAS stock has increased by 37.6% and is now trading at $68.11. View the best growth stocks for 2023 here. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023. View our EXAS earnings forecast. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Monday, November, 1st. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.08. The medical research company had revenue of $456.38 million for the quarter, compared to the consensus estimate of $429.04 million. Exact Sciences had a negative trailing twelve-month return on equity of 22.10% and a negative net margin of 35.73%. During the same quarter last year, the business posted ($0.36) EPS. What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $550.70 million-$552.70 million, compared to the consensus revenue estimate of $506.48 million. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). What is Exact Sciences' stock symbol? Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS." Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (9.03%), Sumitomo Mitsui Trust Holdings Inc. (3.02%), Baillie Gifford & Co. (2.78%), Peregrine Capital Management LLC (0.34%), New York State Common Retirement Fund (0.29%) and Allspring Global Investments Holdings LLC (0.26%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella and Torsten Hoof. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exact Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $68.11. How much money does Exact Sciences make? Exact Sciences (NASDAQ:EXAS) has a market capitalization of $12.10 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.10) on an earnings per share basis. How many employees does Exact Sciences have? The company employs 6,500 workers across the globe. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More How can I contact Exact Sciences? Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701. This page (NASDAQ:EXAS) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.